Cerevel Therapeutics (CERE) News Today → CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (From Banyan Hill Publishing) (Ad) Free CERE Stock Alerts $42.10 -0.25 (-0.59%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 5:10 AM | insidertrades.comN Anthony Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) StockMay 15 at 10:17 AM | stockhouse.comMERGER ALERT CERE Is $45 per CERE Share Fair? Top Law Firm BFA LLP Investigating Cerevel Therapeutics Merger with AbbVieMay 15 at 6:55 AM | insidertrades.comCerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Director Sells $2,105,000.00 in StockMay 14, 2024 | marketbeat.comInsider Selling: Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Director Sells 50,000 Shares of StockCerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Get Free Report) Director N Anthony Coles sold 50,000 shares of the company's stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $42.10, for a total value of $2,105,000.00. Following the sale, the director now owns 15,638 shares in the company, valued at approximately $658,359.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.May 11, 2024 | marketbeat.com108,657 Shares in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Purchased by Versor Investments LPVersor Investments LP bought a new position in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 108,657 shares of the biotechnolMay 10, 2024 | marketbeat.comKellner Capital LLC Invests $861,000 in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Kellner Capital LLC bought a new stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 20,300 shares of the biotechnology company's stock, valued at appMay 9, 2024 | marketbeat.comSegantii Capital Management Ltd Buys Shares of 594,519 Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Segantii Capital Management Ltd purchased a new stake in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 594,519 shares of the biotechnology compaMay 6, 2024 | marketbeat.comBCK Capital Management LP Makes New Investment in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)BCK Capital Management LP bought a new position in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 22,000 shares of the biotechnology company's stock, valued at approximately $933,May 5, 2024 | marketbeat.comInternational Assets Investment Management LLC Purchases Shares of 55,120 Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)International Assets Investment Management LLC acquired a new position in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 55,120 shares of the biotechnology coApril 30, 2024 | finance.yahoo.comAddex stock tanks after lead drug flops in Phase II epilepsy trialApril 26, 2024 | finance.yahoo.comTop 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talksApril 22, 2024 | markets.businessinsider.comHold Rating Maintained for Cerevel Post-Positive Phase 3 Data Amid Pending AbbVie AcquisitionApril 20, 2024 | marketbeat.comCalamos Advisors LLC Makes New Investment in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Calamos Advisors LLC purchased a new position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 305,303 shares of the biotechnology company's stock, valApril 18, 2024 | benzinga.comSoon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease StudyApril 18, 2024 | msn.comAbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drugApril 18, 2024 | reuters.comCerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage studyApril 18, 2024 | finance.yahoo.comCerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s DiseaseApril 18, 2024 | globenewswire.comCerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's DiseaseApril 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)April 12, 2024 | marketbeat.comCerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Short Interest Up 38.2% in MarchCerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 9,620,000 shares, a growth of 38.2% from the March 15th total of 6,960,000 shares. Based on an average daily trading volume, of 1,510,000 shares, the short-interest ratio is currently 6.4 days. Approximately 11.1% of the company's shares are sold short.April 12, 2024 | seekingalpha.comAbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67%April 11, 2024 | marketbeat.comInternational Assets Investment Management LLC Takes Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)International Assets Investment Management LLC purchased a new stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 55,120April 5, 2024 | investing.comCerevel Therapeutics director sells $2.12m in stock, buys $175k worthApril 3, 2024 | uk.finance.yahoo.comDirector N Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings Inc (CERE)April 3, 2024 | marketbeat.comVanguard Group Inc. Purchases 708,826 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Vanguard Group Inc. increased its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 12.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,371,376 shares of the biotechnology company's stockMarch 31, 2024 | marketbeat.com24,487 Shares in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Acquired by SG Americas Securities LLCSG Americas Securities LLC bought a new stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 24,487 shares of the biotechnology cMarch 29, 2024 | wsj.comCerevel Therapeutics Holdings Inc.March 29, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS)March 29, 2024 | marketbeat.comAssenagon Asset Management S.A. Invests $12.72 Million in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Assenagon Asset Management S.A. bought a new stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 299,891 shares of the biotechnolMarch 17, 2024 | marketbeat.comHudson Bay Capital Management LP Invests $1.09 Million in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Hudson Bay Capital Management LP purchased a new stake in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 50,000 shares ofMarch 16, 2024 | finance.yahoo.comCERE Apr 2024 40.000 callMarch 15, 2024 | marketbeat.comGraham Capital Management L.P. Raises Stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Graham Capital Management L.P. raised its position in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 304.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 41,850 shareMarch 13, 2024 | marketbeat.comCerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Sold by Polar Capital Holdings PlcPolar Capital Holdings Plc trimmed its holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 98.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,762 shares of the biotechnology company's stMarch 11, 2024 | marketbeat.comCantor Fitzgerald Research Analysts Lower Earnings Estimates for Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) - Cantor Fitzgerald cut their FY2023 earnings per share (EPS) estimates for shares of Cerevel Therapeutics in a report issued on Wednesday, March 6th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biotechnology company wMarch 7, 2024 | markets.businessinsider.comCerevel Therapeutics: Hold Rating Amidst Pending AbbVie AcquisitionMarch 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Perspective Therapeutics (CATX)March 6, 2024 | marketbeat.comCerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Bought by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. raised its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 100.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,505,976 shares of the biotechnology company's stock after acquiring an additionalMarch 6, 2024 | seekingalpha.comCerevel Therapeutics: Parkinson's Could Be The IssueMarch 5, 2024 | marketbeat.comLake Street Advisors Group LLC Acquires New Shares in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Lake Street Advisors Group LLC purchased a new stake in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The fund purchased 83,857 shares of the biotechnology company's stock, valued at approximatelFebruary 29, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $11.29 Million Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Charles Schwab Investment Management Inc. raised its holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 3.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 517,244 sharesFebruary 28, 2024 | markets.businessinsider.comMaintaining Hold Rating Amid ABBV-CERE Deal Progress and Rising Operational CostsFebruary 28, 2024 | marketbeat.comWestfield Capital Management Co. LP Boosts Stock Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Westfield Capital Management Co. LP boosted its holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 69.3% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 974,483 shares of the biotechnology coFebruary 25, 2024 | marketbeat.comCitigroup Inc. Increases Stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Citigroup Inc. raised its holdings in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 22.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 83,786 shares of the biotechnology comFebruary 24, 2024 | uk.finance.yahoo.comABBV Mar 2024 182.500 callFebruary 23, 2024 | bloomberg.comUS Politicians Raise Concerns Over Capital One-Discover DealFebruary 23, 2024 | uk.finance.yahoo.com3M Healthcare Unit Solventum Joins $53 Billion US Corporate Bond Sales SpreeFebruary 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Intra-Cellular Therapies (ITCI)February 22, 2024 | finance.yahoo.comAbbVie Selling $15 Billion Bonds to Buy ImmunoGen, CerevelFebruary 21, 2024 | reuters.comAbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reportsFebruary 21, 2024 | finance.yahoo.comAbbVie (ABBV) Announces Appointment of New CEO Robert Michael Get Cerevel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter. Email Address Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision. Start streaming it now at no cost here CERE Media Mentions By Week CERE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CERE News Sentiment▼1.120.50▲Average Medical News Sentiment CERE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CERE Articles This Week▼63▲CERE Articles Average Week Get Cerevel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Viking Therapeutics News Today Ascendis Pharma A/S News Today Legend Biotech News Today Jazz Pharmaceuticals News Today Intra-Cellular Therapies News Today Elanco Animal Health News Today Blueprint Medicines News Today Roivant Sciences News Today Cytokinetics News Today Ionis Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CERE) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
